title: Menorrhagia.
abstract: BACKGROUND
  Menorrhagia limits normal activities, and causes anaemia in two thirds of women with objective menorrhagia (loss of 80 mL blood per cycle). Prostaglandin disorders may be associated with idiopathic menorrhagia, and with heavy bleeding due to fibroids, adenomyosis, or use of intrauterine devices (IUDs). Fibroids have been found in 10% of women with menorrhagia overall, and in 40% of women with severe menorrhagia; but half of women having a hysterectomy for menorrhagia are found to have a normal uterus.
  
  
  METHODS
  We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of medical treatments for menorrhagia? What are the effects of surgical treatments for menorrhagia? What are the effects of endometrial thinning before endometrial destruction in treating menorrhagia? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2007 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
  
  
  RESULTS
  We found 39 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
  
  
  CONCLUSIONS
  In this systematic review we present information relating to the effectiveness and safety of the following medical interventions: combined pill, danazol, etamsylate, gonadorelin analogues, intrauterine progesterone, non-steroidal inflammatory drugs (NSAIDs), progestogens, and the following surgical interventions: dilatation and curretage, endometrial destruction, and hysterectomy.
authors.affiliation: Department of Obstetrics and Gynaecology , Milton Keynes Hospital NHS Foundation Trust, Milton Keynes, UK.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Duckitt
authors.forename: Sally
authors.initials: S
authors.lastname: Collins
mesh_terms: D000284:Administration, Oral; D003613:Danazol / Q000494:pharmacology; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006801:Humans; D015994:Incidence; D008595:Menorrhagia / Q000188:drug therapy; D011372:Progestins / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D011372:Progestins; D003613:Danazol